Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2007
Event: Entry into a Material Definitive Agreement via its wholly owned subsidiary, Alphatec Spine, Inc.
Key Financial Metrics and Agreement Terms
This filing details a strategic licensing agreement rather than periodic financial performance. Key financial terms include:
- Upfront Payment: A cash payment payable immediately following the execution of the agreement.
- Milestone Payments: Development and sales milestones payable in cash and common stock, potentially beginning in 2008.
- Equity Obligation: Up to $2,000,000 in aggregate common stock may be issued upon achieving milestones.
- Royalties: Payments based on net sales of licensed products with minimum annual royalties beginning in 2009.
- Term: 20 years.
Note: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Strategic Developments
On December 19, 2007, Alphatec Spine, Inc. entered into an Exclusive License Agreement with Progressive Spinal Technologies LLC (PST). This agreement grants Alphatec Spine an exclusive worldwide license to develop and commercialize PST's "Osteo Technology."
- Technology: An expandable titanium pedicle screw designed for patients with osteoporosis or poor bone density.
- Market Need: Targets patients who are not viable candidates for current standard pedicle screw procedures.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement positions the company to address a specific market segment (osteoporosis/poor bone density) starting with potential milestone achievements in 2008 and royalty obligations in 2009.
Equity Issuance Mechanics:
- Shares will be priced based on the average closing price of the issuer's common stock on the Nasdaq for the 15 trading days prior to issuance.
- If the issuer is not listed on the Nasdaq or a similar national exchange at the time of issuance, Alphatec Spine must issue an equal amount of cash in lieu of stock.
Risks and Termination:
- Alphatec Spine may terminate the agreement for convenience with 90 days' prior written notice.
- Either party may terminate for material uncured breach.
- Unregistered sales of equity securities are subject to resale limitations and investor representations under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact amount of the upfront cash payment, as the filing states a payment is due but does not disclose the specific figure.
- Confirm the specific development and sales milestones required to trigger the $2,000,000 equity obligation.
- Monitor the company's listing status on the Nasdaq to determine if future milestone payments will be made in stock or cash.
- Review the full text of the License Agreement (to be filed in the 2007 Form 10-K) for detailed royalty rates and minimum annual royalty amounts.